Julian Baker’s PTC Therapeutics PTCT Stock Holding History

Julian Baker’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,400	Closed	-$921K	–	97
2024 Q4	$921K	Buy	+20,400	New	+$873K	0.01%	89

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Julian Baker's PTCT Position: Q1 2025 in Review

Julian Baker sold out of PTC Therapeutics (PTCT) in Q1 2025, closing a stake of 20,400 shares — an estimated $921K sold.

Julian Baker first reported a position in PTCT in Q4 2024 and held it in 1 quarter. The position peaked at $921K in Q4 2024. 261 funds tracked by Wall St. Rank hold PTCT as of Q1 2025.

Julian Baker reported no remaining PTC Therapeutics position as of Q1 2025 after selling out during the quarter.
Julian Baker sold 20,400 PTC Therapeutics shares in Q1 2025, an estimated $921K.
Julian Baker first reported a position in PTC Therapeutics in Q4 2024 and held it in 1 quarter.
Julian Baker's PTC Therapeutics position peaked at $921K in Q4 2024.
261 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2025.

Based on Baker Bros. Advisors's 13F filing for Q1 2025, filed 15 May 2025.